Updates

Transforming Preparedness and Response Leaders: Being Ready When Everything Is on the Line

For almost 15 years, NPLI faculty have been observing and teaching preparedness and response leaders in federal, state, and local agencies as well as non-profit and private sector organizations. The core of the NPLI curriculum is the meta-leadership framework and practice method. The program meets on the Harvard campus for one week in December and again for a concluding session in June.

Release of the Refreshed NIMS Doctrine

FEMA released the refreshed National Incident Management System (NIMS) doctrine. NIMS provides a common, nationwide approach to enable the whole community to work together to manage all threats and hazards. NIMS applies to all incidents, regardless of cause, size, location, or complexity.

Clear Talk for First Responders

First responders and emergency management officials have been calling for high-speed, Long-Term Evolution (LTE) cellular devices with three public safety “mission-critical voice” capabilities: push-to-talk, one-to-many, and direct mode. A new computer modeling tool from the National Institute of Standards and Technology (NIST) uses ns-3, an open-source network simulation software to assess factors that could impact the performance of future LTE cellular devices.

Entries in Serious Board Game Award Competition Due 15 January 2018

Entries in the 2018 International Serious Play Awards for tabletop board and card games used in education or training are due 15 January 15 2018.

S&T Helps Train Public Safety Practitioners in Flood Preparation

The third annual National Geospatial Preparedness Summit provided capacity-building training for the public safety community. The Department of Homeland Security Science and Technology (S&T) Directorate First Responders Group provided expertise to support the development of this year’s training program, sessions, workshops, and the functional preparedness exercise based on a real-world flood scenario.

Experimental Ebola Vaccines Elicit Year-Long Immune Response

Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns. These vaccines can elicit immune responses by one month after initial vaccination and last for at least one year. The findings are based on a study of 1,500 adults that began during the West Africa Ebola outbreak.

HHS Pursues Reusable Respirator to Better Protect Medical Providers During Pandemics

An adequate supply of respirators for first responders and healthcare professionals is critical to protecting the health of workers responding to pandemics and other public health emergencies. To meet this need, the Biomedical Advanced Research and Development Authority and Applied Research Associates Inc. will partner to advance the development of respirators that can be reused up to 100 times.

HHS Pursues Therapeutic for Radiation Injury Affecting Blood Platelets

The U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) announced a partnership with Novartis Pharmaceuticals Corporation, to determine whether a product for treating patients suffering from thrombocytopenia could be used to better protect people in the event of a nuclear incident.

Public Health Innovation Impacts Disaster Relief Efforts

Following Hurricane Harvey, colleagues from the United States and Canada deployed to Rockport, Texas, through an unusual disaster relief organization – Field Innovation Team (FIT), a nonprofit organization that creates cutting-edge disaster solutions. They developed a Public Health Digital Brochure (telephone/Short Message Service hotline) and a donation management system that can be adapted to any community after a disaster.

HHS Sponsors Development of Drug to Treat Infections From Biowarfare Agents, Antibiotic-Resistant Bacteria

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, will sponsor the next stages of development of an antibiotic that not only holds potential as a treatment for infections from certain types of drug-resistant bacteria but also may be able to combat infections caused by bacteria used in biowarfare.